Search Results - "Sekeres, M"

Genomic determinants of chronic myelomonocytic leukemia by Patel, B J, Przychodzen, B, Thota, S, Radivoyevitch, T, Visconte, V, Kuzmanovic, T, Clemente, M, Hirsch, C, Morawski, A, Souaid, R, Saygin, C, Nazha, A, Demarest, B, LaFramboise, T, Sakaguchi, H, Kojima, S, Carraway, H E, Ogawa, S, Makishima, H, Sekeres, M A, Maciejewski, J P

“…The biology, clinical phenotype and progression rate of chronic myelomonocytic leukemia (CMML) are highly variable due to diverse initiating and secondary…”
Get full text

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes by Nazha, A, Narkhede, M, Radivoyevitch, T, Seastone, D J, Patel, B J, Gerds, A T, Mukherjee, S, Kalaycio, M, Advani, A, Przychodzen, B, Carraway, H E, Maciejewski, J P, Sekeres, M A

“…The Revised International Prognostic Scoring System (IPSS-R) was developed for untreated myelodysplastic syndrome (MDS) patients based on clinical data. We…”
Get full text

SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts by Visconte, V, Makishima, H, Jankowska, A, Szpurka, H, Traina, F, Jerez, A, O'Keefe, C, Rogers, H J, Sekeres, M A, Maciejewski, J P, Tiu, R V

Get full text

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS by Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., Sanz, G.

“…In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related…”
Get full text

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes by Nazha, A, Al-Issa, K, Hamilton, B K, Radivoyevitch, T, Gerds, A T, Mukherjee, S, Adema, V, Zarzour, A, Abuhadra, N, Patel, B J, Hirsch, C M, Advani, A, Przychodzen, B, Carraway, H E, Maciejewski, J P, Sekeres, M A

Get full text

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms by Traina, F, Visconte, V, Elson, P, Tabarroki, A, Jankowska, A M, Hasrouni, E, Sugimoto, Y, Szpurka, H, Makishima, H, O'Keefe, C L, Sekeres, M A, Advani, A S, Kalaycio, M, Copelan, E A, Saunthararajah, Y, Olalla Saad, S T, Maciejewski, J P, Tiu, R V

“…We hypothesized that specific molecular mutations are important biomarkers for response to DNA methyltransferase inhibitors (DNMT inhibitors) and may have…”
Get full text

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies by Khan, S N, Jankowska, A M, Mahfouz, R, Dunbar, A J, Sugimoto, Y, Hosono, N, Hu, Z, Cheriyath, V, Vatolin, S, Przychodzen, B, Reu, F J, Saunthararajah, Y, O'Keefe, C, Sekeres, M A, List, A F, Moliterno, A R, McDevitt, M A, Maciejewski, J P, Makishima, H

“…Polycomb repressive complex 2 (PRC2) is involved in trimethylation of histone H3 lysine 27 (H3K27), chromatin condensation and transcriptional repression. The…”
Get full text

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides by Zeidan, A M, Sekeres, M A, Garcia-Manero, G, Steensma, D P, Zell, K, Barnard, J, Ali, N A, Zimmerman, C, Roboz, G, DeZern, A, Nazha, A, Jabbour, E, Kantarjian, H, Gore, S D, Maciejewski, J P, List, A, Komrokji, R

“…Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are…”
Get full text

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms by Molenaar, R J, Thota, S, Nagata, Y, Patel, B, Clemente, M, Przychodzen, B, Hirsh, C, Viny, A D, Hosano, N, Bleeker, F E, Meggendorfer, M, Alpermann, T, Shiraishi, Y, Chiba, K, Tanaka, H, van Noorden, C J F, Radivoyevitch, T, Carraway, H E, Makishima, H, Miyano, S, Sekeres, M A, Ogawa, S, Haferlach, T, Maciejewski, J P

“…Mutations in isocitrate dehydrogenase 1/2 ( IDH1/ 2 MT ) are drivers of a variety of myeloid neoplasms. As they yield the same oncometabolite, D…”
Get full text

Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation by Radivoyevitch, T, Sachs, R K, Gale, R P, Molenaar, R J, Brenner, D J, Hill, B T, Kalaycio, M E, Carraway, H E, Mukherjee, S, Sekeres, M A, Maciejewski, J P

“…Risks of acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) are known to increase after cancer treatments. Their rise-and-fall dynamics and…”
Get full text

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies by Makishima, H, Jankowska, A M, Tiu, R V, Szpurka, H, Sugimoto, Y, Hu, Z, Saunthararajah, Y, Guinta, K, Keddache, M A, Putnam, P, Sekeres, M A, Moliterno, A R, List, A F, McDevitt, M A, Maciejewski, J P

Get full text

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium by Zeidan, A M, Al Ali, N, Barnard, J, Padron, E, Lancet, J E, Sekeres, M A, Steensma, D P, DeZern, A, Roboz, G, Jabbour, E, Garcia-Manero, G, List, A, Komrokji, R

“…While therapy-related (t)-myelodysplastic syndromes (MDS) have worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS…”
Get full text

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) by Della Porta, M G, Tuechler, H, Malcovati, L, Schanz, J, Sanz, G, Garcia-Manero, G, Solé, F, Bennett, J M, Bowen, D, Fenaux, P, Dreyfus, F, Kantarjian, H, Kuendgen, A, Levis, A, Cermak, J, Fonatsch, C, Le Beau, M M, Slovak, M L, Krieger, O, Luebbert, M, Maciejewski, J, Magalhaes, S M M, Miyazaki, Y, Pfeilstöcker, M, Sekeres, M A, Sperr, W R, Stauder, R, Tauro, S, Valent, P, Vallespi, T, van de Loosdrecht, A A, Germing, U, Haase, D, Greenberg, P L, Cazzola, M

“…A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based…”
Get full text

Prediction of CR following a second course of ‘7+3’ in patients with newly diagnosed acute myeloid leukemia not in CR after a first course by Othus, M, Mukherjee, S, Sekeres, M A, Godwin, J, Petersdorf, S, Appelbaum, F R, Erba, H, Estey, E

Get full text

The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies by Statler, A, Radivoyevitch, T, Siebenaller, C, Gerds, A T, Kalaycio, M, Kodish, E, Mukherjee, S, Cheng, C, Sekeres, M A

“…To minimize adverse events (AEs) unrelated to drugs and maximize the likelihood of drug approvals, eligibility criteria for randomized controlled trials (RCTs)…”
Get full text

Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies by Gómez-Seguí, I, Makishima, H, Jerez, A, Yoshida, K, Przychodzen, B, Miyano, S, Shiraishi, Y, Husseinzadeh, H D, Guinta, K, Clemente, M, Hosono, N, McDevitt, M A, Moliterno, A R, Sekeres, M A, Ogawa, S, Maciejewski, J P

Get full text

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron by Visconte, V, Avishai, N, Mahfouz, R, Tabarroki, A, Cowen, J, Sharghi-Moshtaghin, R, Hitomi, M, Rogers, H J, Hasrouni, E, Phillips, J, Sekeres, M A, Heuer, A H, Saunthararajah, Y, Barnard, J, Tiu, R V

“…Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring…”
Get full text

Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse? by Zeidan, A M, Sekeres, M A, Barnard, J, Steensma, D P, Komrokji, R

Get full text

Recurrent genetic defects on chromosome 7q in myeloid neoplasms by Hosono, N, Makishima, H, Jerez, A, Yoshida, K, Przychodzen, B, McMahon, S, Shiraishi, Y, Chiba, K, Tanaka, H, Miyano, S, Sanada, M, Gómez-Seguí, I, Verma, A K, McDevitt, M A, Sekeres, M A, Ogawa, S, Maciejewski, J P

Get full text

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts by Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

“…Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic…”
Get full text